成年人复发难治性急性髓系白血病(M3除外)的化疗方案及其研究进展

尽管化疗及造血干细胞移植被应用于急性髓系白血病(AML)的治疗,但仍然有大部分的患者在治疗后复发,少数患者在应用标准一线治疗方案后无法获得完全缓解.复发难治是目前导致AML患者治疗失败的主要原因,是当前AML治疗的重点和难点.对于复发难治性AML目前国际上尚无首选的化疗方案.文章就国内外成年人复发难治性AML(M3除外)的化疗现况及其进展进行综述.

The actual status and the progress of chemotherapy for adults with refractory/relapsed acute myeloid leukemia (except M3)

Although intensive chemotherapy and hematopoietic stem cell transplant (HSCT) are currently used in the treatment of acute myeloid leukemia (AML),a large proportion of patients relapse after treatment.On the other hand,a minority of cases fail to achieve complete remission (CR) after a standard first line treatment.Leukemia relapse and refractory become the main course of treatment failure,which are also the main points and difficulties of treatment for AML.However,the most effective regimen for refractory/relapsed AML has not been established.This review focuses on the progress of the regimens and major chemotherapy for refractory/relapsed AML (except M3).